The role of regulatory T-cells in glioma immunology

Ooi, Yinn Cher; Tran, Patrick; Ung, Nolan; Thill, Kimberly; Trang, Andy; Fong, Brendan; Nagasawa, Daniel T.; Lim, Michael; Yang, Isaac

doi:10.1016/j.clineuro.2013.12.004

Cited by 76 publications

(71 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly to this model, patients with colorectal cancer (CRC) are characterized by an increased Tregs-related IL-10 level, while DCs had lower costimulatory molecule expression and were less able to present antigens to allogeneic T cells [128,129]. Although APCs, monocytes, NK cells, T regulatory, and CD8+ lymphocytes are able to exhibit potent antitoxic action against tumor cells, IL-10 mRNA was detected in melanoma-associated macrophages and lymphocytes, suggesting for facilitated evolution of the primary melanoma and rendering of regional lymph nodes susceptible to metastases [118][119][120][121]130]. In contrast to this case, blood monocytes of endometrial cancer patients show a decrease in IL-10 secretion and co-stimulatory and adhesion factor expression, as well as increased expression of vascular endothelial growth factor receptor 1, indicating that peripheral blood monocytes may induce immunosuppression [119].…”

Section: Principal Immune Conditionsmentioning

confidence: 96%

“…Tumors The immunosuppressive effect of IL-10 is demonstrated in the correlation of tumor progression, survival, and invasion, with IL-10 levels and/or involving degree of IL-10 signaling pathways, such as in melanoma, glioma, endometrial, ovarian, laringeal and pancreatic cancers, or acute myelogenous leukemia [118][119][120][121][122][123][124][125][126]. The IL-10 was found to be uniquely able to convert fully developed DCs to immature macrophage-like cells in a physiologically highly relevant tumor model in mice [127].…”

Section: Principal Immune Conditionsmentioning

confidence: 99%

See 1 more Smart Citation

Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response

Mingomataj

Bakiri

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The interleukin-10 (IL-10) is generally considered as the most important cytokine with anti-inflammatory properties and one of the key cytokines preventing inflammation-mediated tissue damage. In this respect, IL-10 producing cells play a crucial role in the outcome of infections, allergy, autoimmune reactions, tumor development, and transplant tolerance. Based on recent findings with regard to the mentioned clinical conditions, this review attempts to shed some light on the IL-10 functions, considering this cytokine as inherent inducer of the switching immunity. While acute infections and vaccinations are associated by IL-10 enhanced during few weeks, chronic parasitoses, tumor diseases, allergen-specific immunotherapy, transplants, and use of immune-suppressor drugs show an increased IL-10 level along months or years. With regard to autoimmune pathologies, the IL-10 increase is prevalently observed during early stages, whereas the successive stages are characterized by reaching of immune equilibrium independently to disease's activity. Together, these findings indicate that IL-10 is mainly produced during transient immune conditions and the persistent IL-10-related effect is the indication/prediction (and maybe effectuation) of the switching immunity. Actual knowledge emphasizes that any manipulation of the IL-10 response for treatment purposes should be considered very cautiously due to its potential hazards to the immune system. Probably, the IL-10 as potential switcher of immunity response should be used in association with co-stimulatory immune effectors that are necessary to determine the appropriate deviation during treatment of respective pathologies. Hopefully, further findings would open new avenues to study the biology of this "master switch" cytokine and its therapeutic potential.

show abstract

Section: Principal Immune Conditionsmentioning

confidence: 96%

Section: Principal Immune Conditionsmentioning

confidence: 99%

Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response

Mingomataj

Bakiri

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

show abstract

“…All of these strategies show great promise, but limitations arise in their ability to accumulate at the tumor and elicit a strong immune response against the tumor cells. The immunosuppressive nature of the tumor microenvironment, with an increased level of T-regulatory cells and inhibitory immune checkpoints, acts as a barrier in the potency of immunotherapy [5,15]. Thus, nanotechnology has the potential to augment the effects of the novel immunotherapeutic approaches and overcome their limitations if used in the right combinations.…”

Section: Immunotherapy For Gbmmentioning

confidence: 98%

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Ung

Yang

2015

J Neurooncol

Self Cite

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is characterized as one of the most common and most deadly malignant primary brain tumors. Current treatment modalities include the use of surgical resection and adjuvant chemotherapy and radiation therapy, though survival is still limited. Because of this, new treatment strategies are needed to improve overall survival. Immunotherapy has emerged as a potential treatment, but still possesses certain limitations to have a substantial clinical effect. In addition, nanotechnology has emerged as potent treatment effectors that have been shown to augment the effects of therapies including chemotherapy, gene therapy, and more. Nanoparticles possess a novel approach due to the myriad of functional groups that can create targeted treatments, though further optimization is still required. In this review, the authors will present the current uses and abilities of nanotechnology and its implication for use with immunotherapy in the treatment of GBM.

show abstract

“…The systemic impaired immune response in GBM patients can been seen at a gross level with leucopoenia on peripheral blood counts which appears to improve following cytoreductive surgery and decline again at recurrence [58,59]. In terms of T-cell function systemic responses are inhibited through increased circulating Tregs [60]. Within the tumour micro environment inhibitory factors include expression of Fas ligand by the tumour resulting in T-cell apoptosis, high levels of infiltrating Tregs, and an overall inhibitory cytokine milieu.…”

Section: Latency and Reactivationmentioning

confidence: 99%

“…Depletion of Tregs in a mouse model has been shown to provide an anti-tumour effect with improved survival however human data has not been correlated to survival [60,86].…”

Section: Tregsmentioning

confidence: 99%

Characteristics of Human Cytomegalovirus specific T-Cells in Glioblastoma Multiforme

Alexander¹

View full text Add to dashboard Cite

The role of regulatory T-cells in glioma immunology

Cited by 76 publications

References 114 publications

Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response

Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Characteristics of Human Cytomegalovirus specific T-Cells in Glioblastoma Multiforme

Contact Info

Product

Resources

About